Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis

What Was Tested

This registered phase 4 trial tested Semaglutide.

Participants will be randomized 1:1 to either weekly subcutaneous semaglutide versus usual care and followed for 26 weeks.

It had two arms (groups): Usual Care Group (no intervention) and Semaglutide (experimental).

This treatment arm comprises a strategy of usual care for type 2 diabetes mellitus.

Individuals randomized to this arm will take semaglutide once weekly.

The registry classes the interventions as drug.

More on the Plan

The proposed study is a parallel group, pilot randomized controlled trial.

The trial will recruit 100 participants across Canadian hospitals and potentially others worldwide.

The researchers will recruit patients receiving maintenance dialysis for ≥ 90 days who have a background of type 2 diabetes mellitus.

The researchers will exclude patients with type 1 diabetes mellitus and recent recipients of a GLP-1-RA.

Who Took Part

Enrollment: 100 planned participants were the target.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Age ≥ 18. Receiving chronic maintenance hemodialysis or peritoneal dialysis for ≥ 90 days. Confirmed DM2 based on medical history and current or prior receipt of an oral hypoglycemic agent and/or insulin. Ability to provided informed consent or through their substitute decision maker.

The full record lists 4 inclusion and 7 exclusion criteria; among the exclusions: type 1 dm; use of a glp-1-ra within 30 days prior to screening; confirmed pregnancy, women of childbearing potential.

How the Study Was Run

It was run as a randomized, parallel-group and open-label study.

The participants were allocated by chance, so the Semaglutide group and the comparison group should start out alike.

The Semaglutide group and the comparison group ran side by side rather than switching.

Everyone knew when Semaglutide was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

It started in 2025-11-27 with completion listed for 2027-07.

It ran at 2 sites in Canada (2).

Its stated primary purpose is treatment.

What Was Measured

The main thing measured (primary outcome): Adherence of Study Intervention (time frame: 26 weeks).

It also tracked 6 secondary outcomes, for example Study Medication Discontinuation, Feasibility of Study Recruitment, Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability], Major Adverse Cardiovascular Events, Follow Up Percentage at 26 weeks and Patient Reported Measures.

What This Means in Plain Language

Put simply, this is a phase 4, randomized trial of Semaglutide in 100 people.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Semaglutide compound page, all human trials.